S100 proteins modulate p53 activity by interacting with its tetramerization (p53TET, residues 325-355) and transactivation (residues 1-57) domains. In this study, we characterized biophysically the binding of S100A1, S100A2, S100A4, S100A6 and S100B to homologous domains of p63 and p73 in vitro by fluorescence anisotropy, analytical ultracentrifugation and analytical gel filtration. We found that S100A1, S100A2, S100A4, S100A6 and S100B proteins bound different p63 and p73 tetramerization domain variants and naturally occurring isoforms with varying affinities in a calcium-dependent manner. Additional interactions were observed with peptides derived from the p63 and p73 N-terminal transactivation domains. Importantly, S100 proteins bound p63 and p73 with different affinities in their different oligomeric states, similarly to the differential modes of binding to p53. On the basis of our data, we hypothesize that S100 proteins regulate the oligomerization state of all three p53 family members and their isoforms, with a potential physiological relevance in developmental and disease-related processes. The regulation of the p53 family by S100 is complicated and depends on the target preference of each individual S100 protein, the concentration of the proteins and calcium, as well as the splicing variation of p63 or p73. Our results outlining the complexity of the interaction should be considered when studying the functional effects of S100 proteins in their biological context.
Introduction
The family of S100 proteins is a highly conserved group of more than 20 members of small acidic calciumbinding proteins in vertebrates (Donato, 2003) . Their expression has been implicated with neurological disorders, cardiac and inflammatory diseases (Ilg et al., 1996; Mrak and Griffinbc, 2001; Donato, 2003; Dean et al., 2006; Sedaghat and Notopoulos, 2008) . Several S100 proteins have been shown to be valuable biomarkers for cancerous diseases (Salama et al., 2008) . Further, S100 proteins have been linked to processes of neuronal development, cell survival and differentiation (Chan et al., 2003; Buckiova and Syka, 2009) . Similarly to calmodulin, the S100 proteins undergo a conformational change on Ca 2 þ binding. S100 proteins interact with other proteins in a calcium-dependent as well as a calcium-independent manner (Zimmer et al., 2003; Santamaria-Kisiel et al., 2006) . A common feature of S100 proteins is their ability to bind to the tumor suppressor p53. We previously discovered that S100 proteins generally bind to the tetramerization domain (residues and the N-terminal transactivation domain (residues 1-57) of p53. In addition, a subset of the protein family binds to the negative regulatory domain (367-393) of the tumor suppressor. Further, S100 proteins have been shown to potentially activate as well as inhibit p53 (Baudier et al., 1992; Scotto et al., 1998 Scotto et al., , 1999 Rustandi et al., 2000; Grigorian et al., 2001; Lin et al., 2001 Lin et al., , 2004 Fernandez-Fernandez et al., 2005 , 2008 Mueller et al., 2005; Salama et al., 2008; Slomnicki et al., 2009; van Dieck et al., 2009) .
The tumor suppressor p53 has two homologs, p63 and p73. Unlike p53, which is mutated in more than 50% of all tumors (Joerger and Fersht, 2007) , p63 and p73 are rarely mutated in cancers. Nevertheless, overexpression of p63 and p73 is observed in several types of cancer Yamaguchi et al., 2000; Moll and Slade, 2004; Deyoung and Ellisen, 2007; Finlan and Hupp, 2007) . Further, p63 and p73 are involved in several developmental processes (Danilova et al., 2008) . Structurally, the three p53 family members share conserved transactivation, DNA-binding and oligomerization (TET) domains, but differ greatly in their C-terminal region. p63 and p73 full-length proteins have an extended C-terminus including a SAM-domain, which could be involved in oligomerization, proteinprotein and protein-RNA interactions, and a transcription inhibitory domain, which may interact with the p63 or p73 transactivation domain to inhibit transcriptional activity (Serber et al., 2002; Scoumanne et al., 2005) .
Several splice-isoforms have been identified including (TA-) or lacking (DN-) the transactivation domain, and with a full (Àa) or truncated C-terminus (p63b-g, p73b-Z) (Scoumanne et al., 2005) . Overall, more than 50 isoforms have been identified for the p53 family (Rosenbluth and Pietenpol, 2008) , some of them with similar but others even with opposing functions, implying a complicated regulatory network of the p53 family based on splicing. p63 and p73 share great sequence identity with p53, especially in the DNA-binding domain (B 60% identity) (Melino et al., 2003) , the transactivation domain (B30% identity) and the tetramerization domain (B40% identity with p53, B70% identity with each other) (Scoumanne et al., 2005; Vilgelm et al., 2008) .
On the basis of the sequence homology between the tetramerization domain of p53, p63 and p73, we studied whether the members of the S100 family also interact with p63 and p73 in vitro by fluorescence anisotropy, analytical size-exclusion chromatography (SEC) and analytical ultracentrifugation (AUC). We found that binding to the tetramerization domains and the transactivation domains of the p53 family are a common feature of S100 proteins. The binding is calcium dependent and influenced by the oligomerization state of the p53 family. Interestingly, the affinity of S100A1, S100A2, S100A4, S100A6 and S100B is significantly higher for the tetramerization domains of p63 and p73 than for p53. We show that S100 proteins differentially bind tetrameric, dimeric and monomeric p63 and p73, suggesting a common regulatory function for all the p53 family members. The calcium-dependent interaction of S100 proteins with p63 and p73 could be physiologically relevant in developmental as well as disease-related processes.
Results

S100 proteins bind the p63 tetramerization domain in different oligomeric states and influence oligomerization
To quantify the binding of S100 proteins to the tetramerization domain of p63, we overexpressed human S100A1, S100A2, S100A4, S100A6 and S100B in Escherichia Coli and purified them. All five proteins interact with the tetramerization domain of p53 in fluorescence anisotropy experiments (FernandezFernandez et al., 2005 (FernandezFernandez et al., , 2008 . A homologous p63-derived peptide, corresponding to the canonical p53 tetramerization domain region, p63TET(359-390) was chemically synthesized with an N-terminal fluorescein label. S100 proteins were titrated into 0.1 mM of p63TET in physiological ionic strength buffer. We measured dissociation constants (K d ) in the range of 100 nM for S100A1, S100A2, S100A4 and S100A6, and 2.8 mM for S100B (Table 1) . The observed affinities were significantly higher than for the homologous p53TET peptide (Fernandez-Fernandez et al., 2005 , 2008 . Similarly to p53TET, the affinity to p63TET was highly dependent on the concentration of the labelled peptide used in the anisotropy titration experiments, as illustrated by the binding of S100A4 to 0.1, 0.5, 1 and 2 mM p63TET (Figure 1a) . The more TET used in the experiments, the weaker the binding to S100 proteins. When the concentration of labelled peptide was much higher than the K d , it was possible to perform a stoichiometric titration. Titration of S100A4 to 0.5 mM p63TET revealed binding of one dimer S100A4 per monomer p63TET (Figure 1b) . The same stoichiometry was observed in similar experiments for S100A1, S100A2 and S100A6 (data not shown). The binding of S100 proteins to p53 is dependent on calcium (FernandezFernandez et al., 2005 (FernandezFernandez et al., , 2008 van Dieck et al., 2009) . Consequently, we analyzed if S100 proteins can still bind p63TET in the absence of calcium and in the presence of 1 mM ethylene-diaminetetraacetic acid to complex any traces of bivalent cations. We found that S100 proteins were not able to bind p63TET in the presence of ethylene-diaminetetraacetic acid (Figure 1c ). For the direct titrations of S100 proteins to p63TET, we used a buffer of 10 mM CaCl 2 , which is a large excess of calcium, to induce the active conformation of S100 proteins. We performed calcium titrations to monitor how much calcium is needed to induce the binding of S100 proteins to p63TET ( Figure 1d , Table 2 ). For that purpose, we titrated calcium to a solution of p63TET and S100 proteins at concentrations far above the K d in a buffer without calcium. Consequently, the binding of S100 to p63TET was solely dependent on the amount of calcium titrated to the cuvette. We found that far less than 10 mM CaCl 2 was sufficient to induce the interaction, measuring EC 50 values ranging from B5 mM for S100A4 to B 280 mM for S100B.
As the concentration of p63TET in the fluorescence anisotropy experiments was very low, probably containing tetrameric p63TET as well as lower oligomeric forms, we performed analytical SEC with a recombinant p63TET construct at high mM concentrations, in which p63TET could be expected to be tetrameric. Indeed, p63TET eluted as a tetramer as determined by multiangle light scattering. The S100 proteins eluted as dimers (Table 3) . A mixture of S100A1, S100A2, S100A4 or S100A6 and p63TET with a ratio of 2:1 resulted in a single peak with a shift in retention time (t r ) from that of S100 alone (Figure 2 ). According to the multi-angle light scattering detection, the M W corresponding to the peaks of the complexes increased, with the maximum apparent M W increase corresponding to the mass of a p63TET monomer (Table 3 ). This means that the tetramer of p63TET was disrupted through the (Fernandez-Fernandez et al., 2005 , 2008 .
Interaction of S100 proteins with p63 and p73 J van Dieck et al binding of S100 proteins to the monomer. In contrast, S100B did not interact tightly with p63TET: the elution profile showed two separate peaks for S100B (t r B17.5 min) and p63TET (t r B20 min), and no shift in t r for S100B. In addition, the M W for the elution peak of S100B did not change on addition of p63TET (Table 3) . The results were confirmed by analytical SEC, in which the eluted peaks for S100 proteins were collected and analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis. S100A1, S100A2, S100A4 and S100A6 co-eluted with p63TET but S100B did not (data not shown).
Simultaneously performed structural studies on the tetramerization domain of p73 revealed that it contains a C-terminal helical extension, which is essential for stabilizing the overall structure of the tetramer, in addition to the canonical p53 tetramerization domain motif . This additional C-terminal helix is conserved in p63 and stabilizes the p63 tetramer . Consequently, we assumed that this helical region also influences the interaction of p63 and p73 with S100 proteins. As we were not able to purify the p63 tetramerization domain variant (residues 356-411) containing this additional structural element after labelling with fluorescein, we decided to study the interaction of S100 proteins to naturally occurring isoforms containing the fulllength tetramerization domain instead. We, therefore, performed a recombinant protein expression screening of a series of p63 and p73 isoforms (Brandt et al., 2009 ) and were able to express DNp63b and DNp73b in amounts large enough to perform biophysical experiments.
DNp63b is a naturally occurring splice isoform without the N-terminal transactivation domain and the C-terminal SAM domain. It is the most effective DNsplice isoform of p63 for activation of gene expression (Boldrup et al., 2009) . We labelled DNp63b with a Cterminal FlAsH-Tag to perform fluorescence-monitored AUC. The sedimentation velocity ultracentrifugation of DNp63b-FlAsH resulted in three peaks corresponding Figure 1 Fluorescence anisotropy titration of S100A4 to p63TET(359-390). The higher the concentration of fluorescein-labelled p63TET peptide (0.1, 0.5, 1 and 2 mM) used in anisotropy studies in physiological ionic strength (PIS) buffer, the higher the relative amount of tetrameric p63TET and the lower the affinity to S100A4 (a). The stoichiometry of binding was determined by titrating S100A4 into 0.5 mM labelled p63TET (b). In a buffer containing 1 mM ethylene-diaminetetraacetic acid (EDTA) instead of 10 mM CaCl 2 , the binding of S100A4 to p63TET is completely inhibited (c). Calcium activated the binding when titrated to S100A4 and p63TET in a buffer without calcium (d). Table 2 Ca 2 þ activation of binding of S100 proteins to p63TET
Protein EC 50 (mM) S100A1 46.6 ± 7.5 S100A2 48.7 ± 0.7 S100A4 5.4 ± 1.1 S100A6 19.5 ± 2.5 S100B 277.7±56.1
Interaction of S100 proteins with p63 and p73 J van Dieck et al to monomeric, dimeric and tetrameric protein with sedimentation coefficients of B1.2, B1.8 and B3.0 S. On addition of 20 mM S100 protein, the sedimentation profiles changed. An increase in sedimentation coefficient for the labelled DNp63b-FlAsH species would indicate a higher molecular mass, thus formation of a complex with S100 proteins. In the presence of S100A1, the peak for the p63 tetramer had a lower intensity than that of the peak for dimeric p63, indicating a disruption of the DNp63b-FlAsH tetramer into dimers. In the profiles for S100A2 and S100B, a fourth peak appeared with a sedimentation coefficient of B4.0 S, indicating binding of these S100 proteins to tetrameric DNp63b-FlAsH. In the presence of S100A6, an additional peak of B3.5 S appeared in the form of a broad shoulder of the tetramer peak at B3.0 S, also indicating binding of S100A6 to tetrameric DNp63b. For all S100 proteins, the peaks for the DNp63b-FlAsH monomer and dimer shifted to B1.4 S and B2.2 S, indicating binding of S100 proteins to p63 monomers and dimers ( Figure 3a) . We then confirmed the binding of S100 proteins to tetrameric DNp63b in SEC experiments. S100A2, S100A6 and S100B co-eluted with DNp63b whereas S100A1 and S100A4 did not (Figure 3b ). S100 proteins interact with the tetramerization domain of p73 in different oligomeric states We performed fluorescence anisotropy titration with S100 proteins with recombinant p73TET(351-383), which was fluorescein labelled at the N-terminus. As for p63TET, we found K d values in the low nanomolar range for S100A2, S100A4 and S100B (Table 1) . It was not possible to obtain K d values for S100A1 and S100B because of a very low overall change in anisotropy for these proteins (data not shown). We then expressed the recombinant p73TET-long (residues 351-399) comprising the full-length p73 tetramerization domain ) and labelled it with fluorescein at the N-terminus to perform further fluorescence anisotropy titrations. The overall change in the anisotropy experiments was very low. Nevertheless, it was possible to obtain binding curves for S100A4 and S100A6 (Figure 4) . The affinity of p73TET-long was B7 times lower for S100A6 and B10 times lower for S100A4 than the values measured for p73TET (Table 1) but still more than 20 times higher than for p53TET. Owing to the low change in anisotropy, we could not determine a binding curve for S100A1, S100A2 and S100B. The binding to p73TET was calcium dependent (data not shown).
We also studied the interactions of S100 proteins with the splice isoform DNp73b-FlAsH in fluorescencemonitored AUC experiments. As for DNp63b-FlAsH, we obtained three individual peaks for DNp73b-FlAsH in the sedimentation experiments, with sedimentation coefficients of B1.4, B2.0 and B3.1 S corresponding to monomeric, dimeric and tetrameric DNp73b-FlAsH. The largest changes in sedimentation coefficient for tetrameric DNp73b-FlAsH was observed for S100A2 (B4.0 S) and S100A6 (B3.7 S), while smaller shifts were observed for S100A1 (B3.3 S), S100A4 (B3.5 S) and S100B (B3.3 S), indicating a weaker binding of these three proteins to tetrameric DNp73b-FlAsH. We also observed a small shift in sedimentation coefficient for dimeric DNp73b-FlAsH on addition of S100A1, S100A4, S100A6 and S100B to B2.2 S, indicating a complex of these S100 proteins with dimeric DNp73b-FlAsH. We did not detect any sedimentation shifts caused by a binding event to monomeric p73 (Figure 5a ). Analytical SEC for DNp73b revealed a co-elution with S100A2 and S100A6, the two proteins that gave the largest shifts for tetrameric p73 in fluorescence AUC. In contrast, S100A1, S100A2, S100A4 and S100B did not co-elute with DNp73b, suggesting that there was no stable complex formation of these S100 proteins with tetrameric DNp73b (Figure 5b ).
S100 proteins interact with the transactivation domains of p63 and p73
We previously showed that S100 proteins interact with the transactivation domain of p53 in vitro (van Dieck et al., 2009) . Therefore, we synthesized and purified N-terminal peptides of p63 (p63N; residues 5-35) and p73 (p73N; residues 10-40) with a C-terminal Lysmethoxycoumarin label to study in fluorescence anisotropy titration experiments whether S100 proteins interact with the transactivation domains of the p53 homologs as well. For p63N, we observed high-affinity binding, with K d values in the nanomolar range for S100A1, S100A2, S100A4 and S100A6, whereas S100B bound B100 times more weakly (Table 4 and Figure 6 ). We also observed binding of S100 proteins to p73N, but the affinity was up to three orders of magnitude weaker than for p63N, with K d values between 25 and 50 mM for S100A1, S100A2, S100A4 and S100A6. We did not detect an interaction between S100B and p73N (Table 4 and Figure 6 ). No binding was observed for p63N and p73N in a buffer without calcium (data not shown). Theoretical M w of a complex of one S100 dimer with one p63TET monomer.
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Discussion
In this study, we showed that S100 proteins interact with the p53 homologs p63 and p73 in vitro. We characterized the binding biophysically by fluorescence anisotropy titrations, analytical SEC and AUC. We observed a higher affinity of S100A proteins for the tetramerization domains of p63/p73 than for that of p53 ( Table 1 ), suggesting that the p53 homologs could be the preferred targets. In particular, S100A1, S100A2, S100A4 and S100A6 showed a higher affinity for p63TET and p73TET than for p53(293-393). In contrast, S100B was the strongest binder to p53(293-393) (FernandezFernandez et al., 2005 (FernandezFernandez et al., , 2008 but the weakest binder to p63TET ( Table 1 ), implying that p53 is a preferred target of S100B. Further, we noticed that the binding of Figure 2 Analytical SEC of S100 proteins with p63TET(359-390). 100 ml of S100 protein (50-150 mM) were injected in the absence (black) or presence of p63TET (red) in a ratio of one dimer S100 per monomer p63TET. In contrast to all other S100 proteins, the t r of S100B did not change on addition of p63TET.
Interaction of S100 proteins with p63 and p73 J van Dieck et al Figure 3 Binding of S100 proteins to DNp63b. Analytical AUC of 200 nM DNp63b-FlAsH in the absence or presence of 20 mM S100 protein. Differences in the sedimentation profiles imply differential binding to monomeric, dimeric and tetrameric DNp63b by S100 proteins (a). Co-elution of tetrameric DNp63b with S100 proteins in analytical SEC (b); 1: DNp63b þ S100A1, 2: DNp63b þ S100A2, 3: DNp63b þ S100A4, 4: DNp63b þ S100A6, 5: DNp63b þ S100B.
Interaction of S100 proteins with p63 and p73 J van Dieck et al S100 proteins to p63/p73 depended on the length of the construct used, and we observed different binding properties for individual S100 proteins. S100A1 disrupted tetrameric p63TET in analytical SEC experiments (Figure 2 and Table 3 ) and also disrupted tetrameric DNp63b-FlAsH into dimers (Figure 3) . We could not detect binding of S100A1 to tetrameric DNp63b or DNp73b in analytical SEC experiments (Figures 3 and 5) , but we observed a small change in the sedimentation coefficient for tetrameric DNp63b in AUC experiments on addition of S100A1, indicative of weak binding. The results imply that S100A1 binds tightly to lower oligomeric species of p63/p73 but only weakly to tetrameric species compared with other S100 proteins. We previously reported similar results for S100A1 and p53, in which we showed that S100A1 bound tightly to the monomeric mutant L344P of p53(293-393) but not to tetrameric full-length p53 in analytical SEC (van Dieck et al., 2009 ). S100A2 and S100A6 bound monomeric, dimeric as well as tetrameric p63 and dimeric and tetrameric p73 in AUC experiments (Figures 3 and 5) . We previously discovered similar binding properties for p53 (van Dieck et al., 2009) . Interestingly, we observed that S100B bound relatively weakly to p63TET (Table 1) , and did not form a stable complex with a p63TET monomer in analytical SEC, unlike S100A1, S100A2, S100A4 and S100A6 (Figure 2 ). By contrast, S100B was able to bind the tetrameric splice-isoform DNp63b in AUC and SEC experiments. The DNp63b isoform contains the full tetramerization domain, including the additional C-terminal helix, which stabilizes the tetrameric state, whereas p63TET more readily dissociates into lower oligomeric species . Hence, differences in S100B binding could be caused by differences in the oligomerization equilibria or in the molecular surface properties of the full-length p63 tetramerization domain because of the C-terminal helix, in analogy to the structures of different p73 tetramerization domain variants . There is, of course, also the possibility that the observed differences are caused by interaction of S100B with the DNA-binding domain or the linker region in DNp63b.
Interestingly, presence of the additional C-terminal helix in p73TET-long, reduced the affinity to S100 proteins compared with p73TET (Table 1) . Again, this could be the result of shifts in the equilibrium between tetramers, dimers and monomers or differences in the surface complementarity of the different species. We could not detect binding of S100 proteins to monomeric DNp73b-FlAsH in the sedimentation velocity AUC experiments. The inability of S100 proteins to interact with monomers of longer p73 variants comprising the full tetramerization domain, could be the reason for the very low overall anisotropy shift observed in titration experiments with labelled p73TET-long compared with p73TET (Figure 4) , because the change of anisotropy is dependent on the mass difference of bound and unbound state of the labelled component. Further, we could not detect binding of S100B to tetrameric DNp73b, which supports our theory that its primary target within the family is p53 and not its homologs.
We previously suggested a binding model for the interactions of S100 proteins with p53 based on in vitro and in vivo data, in which the effect of S100 proteins on p53 was highly dependent on the concentration of each component in the cell (van Dieck et al., 2009) . The model also seems to be valid for p63 and p73, because S100 proteins bind p63 and p73 in their different oligomeric states. As S100 proteins potentially bind the TET domains as well as the N-terminus of p63 and p73, the effect on different isoforms of the p53 family may also vary. For example, all DN splice isoforms of p63 and p73 can still interact with S100 proteins through their TET domain, with either an inhibitory effect disrupting the tetramer or a stimulating effect by binding to the intact tetramer. This effect of differential binding has already been suggested for p53 (van Dieck et al., 2009) . In addition, the binding of S100 to TAisoforms could also differ depending on the splicevariation at the C-terminus of p63 and p73. The C-terminal inhibitory domain of p63 is able to bind to Interaction of S100 proteins with p63 and p73 J van Dieck et al its N-terminal transactivation domain, and thus may interfere with the binding to S100 proteins. Consequently, the binding of the a form may differ from the b and g variant. Although the C-terminal SAM domain is thought to be monomeric in p63 and p73, it has been shown to be involved in homodimerization in other Figure 5 Binding of S100 proteins to DNp73b. Analytical AUC of 100 nM DNp73b-FlAsH in the absence or presence of 40 mM S100 protein. Differences in the sedimentation profiles imply differential binding to dimeric and tetrameric DNp73b by S100 proteins (a). Co-elution of tetrameric DNp73b with S100 proteins in analytical SEC (b); 1: DNp73b þ S100A1, 2: DNp73b þ S100A2, 3: DNp73b þ S100A4, 4: DNp73b þ S100A6, 5: DNp73b þ S100B.
Interaction of S100 proteins with p63 and p73 J van Dieck et al proteins involved in development (Deyoung and Ellisen, 2007) . Consequently, splice isoforms with or without this domain may respond differently to binding of S100 proteins to the TET domain, altering the effect on the overall oligomerization state. The interaction network is further complicated by the fact that different spliceisoforms (for example, DN-and TA-isoforms) can heterotetramerize (Deyoung and Ellisen, 2007) , providing even more diverse interaction combinations for S100 proteins. On the basis of the binding properties of S100 proteins to individual domains of p63 and p73 portrayed here, it would be interesting to study the effects of S100 proteins on all of the B 50 isoforms of the p53 family as well as their known heterotetrameric combinations. But, given the complexity of possible interactions, it is clear that the binding of S100 proteins will be difficult to study in vivo. Transactivation assays with overexpressed (and therefore mostly tetrameric) proteins will most likely only detect binding of S100 proteins to tetrameric p63 and p73 but not binding to lower oligomeric forms, which are also present at physiological concentrations of the proteins. Knock-out of a particular S100 protein in animal models may not necessarily show conclusive effects because of possible overlapping functions of the S100 family members in their binding to the p53 family. The interactions of S100 proteins with p63 and p73 are likely to be physiologically relevant. The interaction of several S100 proteins with p53 has been firmly established in vitro and in vivo in several studies (Baudier et al., 1992; Scotto et al., 1998 Scotto et al., , 1999 Grigorian et al., 2001; Lin et al., 2001 Lin et al., , 2004 Fernandez-Fernandez et al., 2005 , 2008 Mueller et al., 2005; Slomnicki et al., 2009; van Dieck et al., 2009) . It is, therefore, reasonable to assume that the interactions with the paralogs p63 and p73 also occur in vivo. S100 proteins have been shown to be involved in differentiation processes and are usually expressed in a tissue-specific manner, and it is established that p63 and p73 are also involved in developmental processes (Fano et al., 1995; Zimmer et al., 1995; Ilg et al., 1996; Mills et al., 1999; Yang et al., 1999 Yang et al., , 2000 Chan et al., 2003; Donato, 2003; Buckiova and Syka, 2009; Vigliano et al., 2009) . S100A2 has been shown to be a target gene of p63 and p73 (Lapi et al., 2006; Kirschner et al., 2008) . An interaction of the two proteins with S100A2 could be part of a feedback loop mechanism. Further, this interaction may be relevant in the development of cancer, because S100A2 and p63 have been linked to squamous cell carcinomas Lauriola et al., 2000; Yamaguchi et al., 2000; Pelosi et al., 2002; Pruneri et al., 2002; Dotto and Glusac, 2006) .
The interaction of S100 proteins with the p63 and p73 tetramerization domain could constitute a fundamental regulatory mechanism, because almost all known splice isoforms of the p53 family contain a functional tetramerization domain, which could interact with members of the S100 protein family in developmental as well as disease-related processes. As S100 proteins interact with the p53 family in a calcium-dependent manner, our findings may contribute to elucidate, how calcium as a second messenger is involved in developmental processes (Langenbacher and Chen, 2008; Whitaker, 2008) , linking calcium signalling to p63/p73 through the S100 protein family. Binding of S100 proteins in fluorescence anisotropy titrations to p63/p73 N-terminal peptides. S100 proteins with the exception of S100B bind to p63N(3-35) with a nanomolar affinity (a). The binding to p73N(10-40) has a lower affinity (b).
Materials and methods
Plasmids and protein expression
The expression and purification of recombinant human S100A1, S100A2, S100A4, S100A6 and S100B in Escherichia coli C41 cells were as described, using the same pRSET plasmids (FernandezFernandez et al., 2005 (FernandezFernandez et al., , 2008 . The complementary DNA of p63TET, p73TET and p73TET-long were cloned into pRSET vectors with an additional N-terminal His-tag, a lipoyl domain and a thrombin cleavage site. The recombinant proteins were expressed in E. coli BL21 cells and purified through a metal (Nickel) affinity chromatography step. The His-tag and the lipoyl domain were cut off with thrombin (Sigma, Dorset, UK) overnight, and the p63 or p73 proteins were further purified using a second Ni-affinity column, anion exchange chromatography and gel filtration (Superdex 75, GE Healthcare, Little Chalfont, UK). DNp63b and DNp73b with and without a tetracysteine FlAsH-Tag motif were cloned according to the InFusion cloning system protocol (Clontech, Saint-Germainen-Laye, France) into a pET24aHLTEV vector containing an N-terminal 6xHis tag, followed by a lipoyl domain and a TEV protease cleavage site. The proteins were expressed in E. coli B834 cells at 18 1C for 16-20 h and purified by Ni-affinity chromatography and gel filtration.
Peptide synthesis
The fluorescein-labelled p63TET(359-390) was synthesized according to a solid-phase Fmoc/tBu strategy on a rinkamide resin. Before deprotection and cleavage from the resin, the peptides were labelled with 5 0 and 6 0 carboxyfluorescein succimidyl ester at the N-terminus. The p63TET(359-390) peptide was then high performance liquid chromatographypurified on a preparative C18 column with a gradient from 20-80% solvent B (solvent A: 0.1% TFA in water, solvent B: 0.1% TFA, 5% water in acetonitrile). N-terminal peptides p63N(5-35) and p73N(10-40) were synthesized with a Lysmethoxycoumarin at the C-terminus and purified as described earlier (Burge et al., 2009 ).
Protein labelling p73TET and p73TET-long were labelled at the N-terminus with an equimolar amount of 5 0 (and 6 0 ) carboxyfluorescein succimidyl ester (Molecular Probes, Eugene, OR, USA). The fluorescent dye was dissolved in dimethylsulfoxide (B40 mM), and an equimolar amount was added to the protein in a buffer of 20 mM potassium phosphate pH 7.0, 20 mM NaCl. The labelling reaction was monitored by matrix-assisted laser desorption/ionization-time of flight and quenched after 2-3 h with 1 M TRIS pH 7.0 buffer in excess. The peptide was then purified on an analytical C18-high performance liquid chromatography column with a gradient from 40-65% solvent B. FlAsH-tagged DNp63b and DNp73b were labelled with 1.5 equivalents of FlAsH-EDT2 (Invitrogen, Paisley, UK) at 8 1C for 2.5 h.
Fluorescence anisotropy
The experiments were carried out in a physiological ionic strength buffer (PIS) containing 25 mM Tris pH 7.4, 10 mM CaCl 2 , 99.2 mM NaCl and 1 mM dithiothreitol or 25 mM Tris pH 7.4, o0.1 mM CaCl 2 , 1mM ethylene-diaminetetraacetic acid, 99.2 mM NaCl and 1 mM dithiothreitol (PIS-Ca). Fluorescence anisotropy titrations were performed on a Perkin-Elmer LS-55 (Perkin Elmer, Waltham, MA, USA) and a Cary Eclipse Varian fluorescence spectrophotometer (Varian, Walnut, CA, USA) equipped with a Hamilton microlab M dispenser (Hamilton Robotics, Birmingham, UK) under the same conditions as described earlier (Fernandez-Fernandez et al., 2005 , 2008 van Dieck et al., 2009) . The concentration of labelled peptide was usually 0.1 mM for p63TET and p73TET peptides, and 0.2 mM for p63N and p73N unless stated otherwise. The titration data were fitted to a quadratic fitting equation for a single-site binding model, when necessary with the addition of a term accounting for linear drift (Teufel et al., 2007) . Each experiment was performed at least three times, including measurements with different protein and peptide batches. Calcium titrations were performed with 10 mM S100 protein (100 mM for S100B) and 0.1 mM fluorescein-labelled p63TET in 25 mM Tris pH 7.4, 99.2 mM NaCl and 1 mM dithiothreitol in the cuvette, and CaCl 2 ranging from 250 mM to 100 mM in the same buffer was used as titrant. The concentration of calcium at 50% of maximal excitation (EC 50 ) was determined with either a sigmoidal fit or a single-site fit, depending on the shape of the activation curve.
Analytical ultracentrifugation
Fluorescence-monitored AUC sedimentation velocity experiments were performed in a Beckman-Coulter Optima XL-1 (Beckman-Coulter, Brea, CA, USA) with an Aviv fluorescence detection system (MacGregor et al., 2004) . Proteins were buffer exchanged into 20 mM Tris 7.4, 150 mM NaCl, 10 mM CaCl 2 , 10% glycerol, 15 mM b-mercaptoethanol and 0.2% bovine serum albumin. The concentration of DNp63b-FlAsH was 200 nM and 100 nM for DNp73b-FlAsH in the experiments. The concentration of S100 proteins was 20 or 40 mM. The sample volume was 100 ml. The experiments were performed as described earlier (Rajagopalan et al., 2008; van Dieck et al., 2009) , and the sedimentation coefficients were determined using the SedFit software (www.analyticalultracentrifugation.com) (Schuck, 2000) .
Analytical SEC Analytical SEC with recombinant p63TET was performed on a GE Healthcare Superdex Tm 75 analytical gelfiltration column under the same conditions as described earlier (van Dieck et al., 2009) . Proteins were buffer exchanged in physiological ionic strength buffer and 100 ml of protein in concentrations between 50 and 250 mM were injected. The eluted peaks were either collected with a fraction collector and analyzed by SDSpolyacrylamide gel electrophoresis or the weight-averaged molar mass (M W ) was determined on-line by multi-angle light scattering (Wyatt Technology, Santa Barbara, CA, USA) (van Dieck et al., 2009) . SEC with DNp63b and DNp73b were performed on a Superose Tm 6 10/300GL column (GE Healthcare) with a flow of 0.7 ml/min in a buffer of 20 mM Tris 7.4, 150 mM NaCl, 10 mM CaCl 2 10% glycerol, 1 mM dithiothreitol. 100 ml of 10mM DNp63b or DNp73b were injected in the presence of excess S100 protein (50-250 mM). The eluted DNp63b or DNp73b was collected with a fraction collector, concentrated with a centrifugational filter and analyzed by SDS-polyacrylamide gel electrophoresis to detect co-elution with S100 proteins.
